Michael J. Yang
Michael J. Yang's purchase track record
Michael J. Yang has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/14/2024 | PCRX | $26K | +31.9% | +117.6% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Transaction History
| PCRX | ▲ Buy | Grant | 6,405 | $0 | 6/10/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,930 | $0 | 1/15/2026 | View on chart |
| IONS | ▲ Buy | Option Exercise | 4,079 | $0 | 7/15/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 6,163 | $0 | 6/11/2025 | View on chart |
| IONS | ▲ Buy | Option Exercise | 1,931 | $0 | 1/15/2025 | View on chart |
| PCRX | ▲ Buy | Open Market | 2,000 | $26K | 8/14/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.